Welcome to our dedicated page for AVROBIO news (Ticker: AVRO), a resource for investors and traders seeking the latest updates and insights on AVROBIO stock.
AVROBIO, Inc. (symbol: AVRO) is a pioneering clinical-stage gene therapy company dedicated to transforming the lives of patients with cancer and rare genetic diseases. The company focuses on developing potentially curative ex vivo lentiviral gene therapies, offering hope for long-term, potentially lifelong benefits from a single-dose treatment regimen.
AVROBIO's innovative pipeline includes several promising product candidates:
- AVR-RD-04: Designed for the treatment of cystinosis, a rare metabolic disorder that can lead to kidney and eye complications.
- AVR-RD-02: Targeting Gaucher disease type 1, which affects the spleen, liver, and bone marrow, this therapy aims to significantly improve patients' quality of life.
- AVR-RD-05: Developed to combat Hunter syndrome (MPS II), a disorder impacting cognitive development and physical health.
- AVR-RD-03: Intended for the treatment of Pompe disease, a condition that leads to progressive muscle weakness and respiratory failure.
AVROBIO is committed to advancing its clinical programs and leveraging strategic partnerships to enhance the development and commercialization of its therapies. The company continually updates the market with the latest progress and achievements through press releases and collaborations with other industry leaders.
The latest news from AVROBIO includes significant updates on clinical trials, technological advancements, and strategic partnerships. For instance, new collaborations with Tectonic Therapeutic, Inc. underscore AVROBIO's commitment to innovation and expanding its therapeutic reach. Financially, AVROBIO remains focused on maintaining a solid financial foundation to support its ambitious research and development activities.
With a mission to deliver transformative therapies to patients with unmet medical needs, AVROBIO is at the forefront of the gene therapy revolution, continually pushing the boundaries of what is possible in the treatment of rare diseases.
AVROBIO, a clinical-stage gene therapy company, reported safety data from its gene therapy trials for Fabry disease and Gaucher disease at the ESGCT conference. No adverse events related to drug products were observed in 14 trial participants treated. The FAB-GT trial data, with a mean follow-up of 16 months, supports a predictable safety profile. The company introduced novel techniques for monitoring gene therapy safety on a cellular level. The safety evaluations were conducted on patients treated using the proprietary plato® gene therapy platform.
AVROBIO, Inc. (NASDAQ: AVRO) has granted non-statutory stock options for the purchase of 201,750 shares to eight new employees as inducement awards. The options, granted on October 1, 2021, have an exercise price of $5.64 per share, the closing price on the grant date. This initiative aims to attract talent to aid in AVROBIO's mission of developing gene therapies for genetic diseases. The stock options vest over four years, with the first 25% vesting after one year of employment.
AVROBIO, Inc. (NASDAQ: AVRO) announced the granting of stock options for 83,750 shares to four new employees as part of its 2019 Inducement Plan. The stock options, issued on Sept. 1, 2021, have an exercise price of $6.76 per share, matching the closing price on that date. These options have a 10-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly. This strategic move aims to attract and retain talent, enhancing the company's mission in gene therapy development.
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company, announced participation in four upcoming virtual investor conferences. The conferences include:
- Citi’s 16th Annual BioPharma Virtual Conference: Sept. 8-10, 2021 (1x1 meetings only)
- Wells Fargo Virtual Healthcare Conference: Sept. 9, 2021, at 8:40 a.m. ET
- Morgan Stanley Virtual Healthcare Conference: Sept. 14, 2021, at 1:15 p.m. ET
- SVB Leerink CybeRx Series: Sept. 22-23, 2021 (1x1 meetings only)
Live webcasts will be available on the AVROBIO website.
AVROBIO (Nasdaq: AVRO) reported a net loss of $31.4 million for Q2 2021, up from $28.8 million in Q2 2020, primarily due to increased R&D costs. The company is progressing on multiple clinical trials for lysosomal disorders, focusing on Fabry disease, cystinosis, and Gaucher disease. AVROBIO plans to share updated safety data and engage with regulatory agencies for potential registration trials in 2022. Cash reserves stand at $226.4 million, sufficient to fund operations into Q1 2023.
AVROBIO, a clinical-stage gene therapy company, granted stock options to five new employees totaling 75,500 shares under its 2019 Inducement Plan. These options, issued on August 2, 2021, have an exercise price of $7.58 per share, equating to the closing price on the grant date. The options vest over four years, with 25% vesting after the first anniversary. This move is part of AVROBIO's strategy to enhance its workforce, supporting its mission to develop gene therapies for genetic diseases.
AVROBIO (Nasdaq: AVRO), a clinical-stage gene therapy company, announced participation in two upcoming investor conferences. The BTIG Virtual Biotechnology Conference is set for August 9, 2021, at 3:30 p.m. ET, while the Wedbush PacGrow Healthcare Virtual Conference will take place on August 11, 2021, at 1:00 p.m. ET. AVROBIO focuses on personalized gene therapy designed to treat genetic diseases with a single dose and has clinical programs targeting diseases like Fabry and Gaucher disease.
AVROBIO (Nasdaq: AVRO) has granted non-statutory stock options for up to 14,500 shares of common stock to two new employees under its 2019 Inducement Plan. The options, approved by the Compensation Committee, were awarded on July 1, 2021, at an exercise price of $9.28 per share, aligning with AVROBIO's closing stock price on that date. The options have a 10-year term and vest over four years, contingent on the employees' continued service. This move reflects the company's strategy to attract talent while navigating the competitive gene therapy landscape.
AVROBIO (Nasdaq:AVRO), a clinical-stage gene therapy company, announced that its president and CEO, Geoff MacKay, will present at the JMP Securities Life Sciences Conference on June 17, 2021, at 10:30 a.m. ET. A live webcast will be accessible on the Company's website, with an archived recording available for 90 days. AVROBIO aims to provide personalized gene therapy to combat genetic diseases using its plato® gene therapy platform. The company is advancing clinical programs for Fabry disease, Gaucher disease type 1, and cystinosis, and is headquartered in Cambridge, Massachusetts.
FAQ
What is the current stock price of AVROBIO (AVRO)?
What is the market cap of AVROBIO (AVRO)?
What does AVROBIO, Inc. specialize in?
What are the key products in AVROBIO's pipeline?
How does AVROBIO's gene therapy work?
What recent achievements has AVROBIO announced?
What is the financial condition of AVROBIO?
Who are AVROBIO's partners in their gene therapy development?
What is the significance of AVROBIO's work on rare diseases?
What is ex vivo lentiviral gene therapy?
How does AVROBIO intend to deliver their therapies to patients?
Where can I find the latest news about AVROBIO?
